Literature DB >> 18300771

Blood and marrow transplant for lymphoma patients with HIV/AIDS.

Nina D Wagner-Johnston1, Richard F Ambinder.   

Abstract

PURPOSE OF REVIEW: Important strides in the management of patients with HIV/AIDS-related lymphomas have been made in recent years. This review will discuss the role of bone marrow or peripheral stem-cell transplantation as a modality for patients with HIV and lymphoma. RECENT
FINDINGS: In the era of highly active antiretroviral therapy, patients with HIV-associated lymphoma are generally being treated with standard or only slightly modified chemotherapy regimens. Autologous bone marrow and stem-cell transplant approaches in lymphoma patients have been successful. Case reports suggest that allogeneic transplantation for patients with HIV and hematologic malignancies merits further investigation.
SUMMARY: High-dose hematopoietic stem-cell therapies with curative intent should be considered as standard therapeutic options in patients who otherwise are appropriate for such therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18300771      PMCID: PMC4138614          DOI: 10.1097/CCO.0b013e3282f5101e

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  25 in total

1.  Successful allogeneic bone marrow transplant in an HIV-1-positive man with chronic myelogenous leukemia.

Authors:  P Schlegel; P Beatty; R Halvorsen; J McCune
Journal:  J Acquir Immune Defic Syndr       Date:  2000-07-01       Impact factor: 3.731

2.  AIDS-related malignant lymphoma: results of prospective treatment trials.

Authors:  P S Gill; A M Levine; M Krailo; M U Rarick; C Loureiro; L Deyton; P Meyer; S Rasheed
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

3.  Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia.

Authors:  Federica Sorà; Andrea Antinori; Nicola Piccirillo; Andrea De Luca; Patrizia Chiusolo; Antonella Cingolani; Luca Laurenti; Sergio Rutella; Luigi Ortona; Giuseppe Leone; Simona Sica
Journal:  Exp Hematol       Date:  2002-03       Impact factor: 3.084

4.  Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.

Authors:  Elizabeth M Kang; Moniek de Witte; Harry Malech; Richard A Morgan; Sheila Phang; Charles Carter; Susan F Leitman; Richard Childs; A John Barrett; Richard Little; John F Tisdale
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

5.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Authors:  Richard F Little; Stefania Pittaluga; Nicole Grant; Seth M Steinberg; Mark F Kavlick; Hiroaki Mitsuya; Genoveffa Franchini; Martin Gutierrez; Mark Raffeld; Elaine S Jaffe; Gene Shearer; Robert Yarchoan; Wyndham H Wilson
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

6.  Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.

Authors:  Michele Spina; Jean Gabarre; Giuseppe Rossi; Marco Fasan; Clara Schiantarelli; Ezio Nigra; Maurizio Mena; Andrea Antinori; Adriana Ammassari; Renato Talamini; Emanuela Vaccher; Giampiero di Gennaro; Umberto Tirelli
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

7.  Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.

Authors:  Thomas R Spitzer; Richard F Ambinder; Jeannette Y Lee; Lawrence D Kaplan; William Wachsman; David J Straus; David M Aboulafia; David T Scadden
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

8.  High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.

Authors:  Jean Gabarre; Anne-Geneviève Marcelin; Nabih Azar; Sylvain Choquet; Vincent Lévy; Yves Lévy; Roland Tubiana; Frédéric Charlotte; Françoise Norol; Vincent Calvez; Michele Spina; Jean-Paul Vernant; Brigitte Autran; Véronique Leblond
Journal:  Haematologica       Date:  2004-09       Impact factor: 9.941

9.  Protease inhibitors potentiate chemotherapy-induced neutropenia.

Authors:  Mark Bower; Neil McCall-Peat; Natalie Ryan; Liz Davies; Anne Marie Young; Srirupa Gupta; Mark Nelson; Brian Gazzard; Justin Stebbing
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

10.  High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy.

Authors:  Alessandro Re; Chiara Cattaneo; Mariagrazia Michieli; Salvatore Casari; Michele Spina; Maurizio Rupolo; Bernardino Allione; Annamaria Nosari; Clara Schiantarelli; Mariagrazia Vigano; Immacolata Izzi; Piero Ferremi; Arnalda Lanfranchi; Mauro Mazzuccato; Gianpiero Carosi; Umberto Tirelli; Giuseppe Rossi; Maurizio Mazzuccato
Journal:  J Clin Oncol       Date:  2003-10-27       Impact factor: 44.544

View more
  1 in total

Review 1.  Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years.

Authors:  G Hütter; J A Zaia
Journal:  Clin Exp Immunol       Date:  2011-03       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.